ReviewMolecules (Basel, Switzerland)2021
Drugs That Changed Society: History and Current Status of the Early Antibiotics: Salvarsan, Sulfonamides, and β-Lactams.
Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neurosyphilis-Induced Psychosis in Europe: A Systematic Review of Case Reports.Pathogens (Basel, Switzerland) · 2024Pooled it
- Novel Bacterial Topoisomerase Inhibitors: A New Front in an Old War.Journal of molecular biology · 2026Review
- Highly chemoselective access to alkyl-sulfur compounds via NNature chemistry · 2026Article
- A multi-center, open-label, two-part study to investigate the effect of renal function and hemodialysis on the pharmacokinetics of the novel β-lactamase inhibitor nacubactam.Antimicrobial agents and chemotherapy · 2026Article
- Synthesis, Characterization, and Biological Evaluation of Noble Metal Complexes with 2‑(1-Benzyl‑1ACS omega · 2026Article
- Metalloids: Semi as Metals yet Full of Antimicrobial Potential.ChemMedChem · 2026Review
- Antimicrobial Consumption and Resistance Dynamics Across Healthcare Level: Global Evidence and Stewardship Implications.Pathogens (Basel, Switzerland) · 2026Review
- Therapeutic advances in the fight against microbial resistance: innovative strategies and future challenges.Folia microbiologica · 2026Review
- Intervention studies and antimicrobial resistance in Italy: An overview of the latest evidence.Journal of global antimicrobial resistance · 2026Review
- Review
- In vitro and in vivo antibacterial activities and phytochemical screening of 80% methanol extract from Ehretia cymosa leaves.PloS one · 2026Article
- Revolutionizing Antibiotic Delivery: Harnessing 3D-Printing Technology to Combat Bacterial Resistance.Current pharmaceutical design · 2026Review
- Design and Development of Sulfonamide-Chalcones as Antiepileptic Candidates: Computational and Zebrafish-Based Validation Approaches.ACS omega · 2025Article
- Flufenamic acid-based sulfonohydrazide and acetamide derivatives NSAI as inhibitors of multi-targets COX-1/COX-2/5-LOX: design, synthesis, in silico ADMET and binding mode studies.BMC chemistry · 2025Article
- Engineered bacteriophages for therapeutic and diagnostic applications.Disease models & mechanisms · 2025Review
- Reconstructing the Antibiotic Pipeline: Natural Alternatives to Antibacterial Agents.Biomolecules · 2025Review
- Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.RSC advances · 2025Review
- Resorcinol-based Bolaamphiphilic Quaternary Ammonium Compounds.ChemMedChem · 2025Article
- National antibiotic consumption is strongly related to the prevalence of antibiotic resistance across bacterial clades.iScience · 2025Article
- Factors Influencing Antibiotic Prescribing and Antibiotic Resistance Awareness Among Primary Care Physicians in Poland.Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The appearance of antibiotic drugs revolutionized the possibilities for treatment of diseases with high mortality such as pneumonia, sepsis, plaque, diphtheria, tetanus, typhoid fever, and tuberculosis. Today fewer than 1% of mortalities in high income countries are caused by diseases caused by bacteria. However, it should be recalled that the antibiotics were introduced in parallel with sanitation including sewerage, piped drinking water, high standard of living and improved understanding of the connection between food and health. Development of salvarsan, sulfonamides, and β-lactams into efficient drugs is described. The effects on life expectancy and life quality of these new drugs are indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.